Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: CYBERKEN who wrote (1119)	10/27/1998 1:22:00 AM
From: David S.	Read Replies (1) \| Respond to of 1510

There is a 6 foot long model of the amylin molecule (whatever the hell it is called) in the lobby of Amylin. It might be neat to get real stoned and stare at it some night. Maybe we could buy it?

To: CYBERKEN who wrote (1119)	10/27/1998 7:33:00 AM
From: Emec	Respond to of 1510

Cyberken, IMNR is one company that will NEVER run out of cash. Their problem will be what to do with all their cash.

To: CYBERKEN who wrote (1119)	10/27/1998 8:29:00 AM
From: John S. Baker	Read Replies (2) \| Respond to of 1510

No doubt, David, that bio-tech development companies involve considerable risk, and from time to time provide a sufficient return to justify that risk. But IMNR is clearly not a one-product company. They have a variety of applications of their T-cell technology coming along (for everything from psoriasis to prostate cancer), so I personally consider the risk to be somewhat lessened. Nevertheless, Happy Due Diligence! This stuff is not for widows and orphans, and nothing is guaranteed. JSb.